IRIDEX CORP: directors' dealings · United States · SEC (Form 4)

About IRIDEX CORP

IRIDEX Corporation (ticker: IRIX) is a U.S.-based ophthalmic medical technology company listed on Nasdaq in the United States, part of the NYSE/NASDAQ universe followed by global equity investors. The company was founded in 1989 as IRIS Medical Instruments, Inc., later renamed IRIDEX Corporation in 1996, and has long been associated with Silicon Valley. Its executive offices remain in Mountain View, California, although in February 2026 the company announced plans to relocate its headquarters to San Jose to lower operating costs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006045/000119312526140194/irix-20260103.htm)) IRIDEX focuses on the development, manufacturing, and commercialization of therapeutic laser systems, delivery devices, and single-use consumable instrumentation for ophthalmology. Its core addressable markets are glaucoma and retinal diseases, including diabetic macular edema (DME). Key product families include the Cyclo G6® laser system for glaucoma, the Iridex 532® and Iridex 577® lasers, and the proprietary MicroPulse® technology, which the company positions as a differentiated laser treatment designed to be safer and more tissue-sparing than conventional continuous-wave laser approaches. Consumable probes and delivery accessories are an important part of the product stack and help support recurring revenue. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006045/000119312526140194/irix-20260103.htm)) From a competitive standpoint, IRIDEX is a niche specialist rather than a broad-line ophthalmic equipment conglomerate. Its investment case rests on clinical differentiation, installed base, and scientific validation, particularly around MicroPulse applications in glaucoma management and retinal therapy. That specialization can be an advantage in targeted indications where surgeons value precision, safety, and repeatability, but it also means the company operates in a competitive, innovation-driven market where reimbursement, adoption rates, and physician preference matter materially. ([iridex.gcs-web.com](https://iridex.gcs-web.com/news-releases/news-release-details/iridex-reports-fourth-quarter-and-full-year-2025-financial?utm_source=openai)) Geographically, the company sells primarily in the United States through a direct sales force, while international business is handled mainly through independent distributors. Its 2025 Form 10-K states that products were sold in the U.S. and Germany directly, and in other international markets via Topcon Corporation and additional distributors, including Italy, the U.K. (glaucoma), India, and smaller markets. The company also stated that its products are sold into more than 100 countries. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006045/000119312526140194/irix-20260103.htm)) Recent company developments have been noteworthy. In March 2026, IRIDEX reported full-year 2025 revenue of $52.7 million versus $48.7 million in 2024, while narrowing net loss to $4.4 million from $8.9 million. In 2025 and early 2026, it highlighted clinical publications supporting MicroPulse, launched a U.K. study in diabetic macular edema, appointed Patrick Mercer as CEO in October 2024, announced a strategic investment in March 2025, and disclosed its headquarters relocation plan in February 2026. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006045/000119312526140194/irix-20260103.htm))